Pirouette Medical (YC S21)

Life-saving injections as easy as pushing a button

Print
Claim My Business
Security Type
CAFES
Categories
Technology, Other, Financial Services, Healthcare & Medical
Min Investment
$100
Location
Portsmouth, NH
Expected Close Date
April 30, 2025
Target Raise
$50.00K-$1.24M
No. Investors
732
Security Price
$1
Number of Employees
13
Cash
$2,094,498
Revenue
$0
Short Term Debt
$190,461
Cost of Goods
$0
Long Term Debt
$4,271,434
Net Income
$-3,597,016

Key Deal Facts

Backed by Y Combinator & leading VCs including Safar Partners, Liquid 2 Ventures, & Gaingels
Led by 3 rocket scientists from MIT, Harvard Medical School, Harvard Business School, GE, & NASA
18 patents awarded & 7 patents pending– Pirouette owns all IP
Awarded $327K Phase I SBIR grant from NIH & the National Institute on Drug Abuse (NIDA)
Targeting FDA approval & commercialization by 2027
$600B injectable drug delivery market
Forecasting $400M+ in revenue within 5 years (not guaranteed)
93% of surveyed patients (n=918) & 70% of surveyed prescribers (n=258) want to switch to Pirouette

Management Team / Advisory Board Bios

Conor R. Cullinane, Ph.D. President & CEOEngineering ace & healthcare innovation executive. Former NASA & Mass General. Innovations span rockets, spacesuits, and prosthetics. Clarkson University - Aeronautical Engineering BS. MIT/Harvard Medical School - Medical Engineering & Medical Physics PhD, Elijah KapasCTOAuto-injector tech genius. Expertise in FDA regulation and intellectual property strategy. Managed $2M budget at Bechtel, global engineering & construction company. Former GE Manufacturing Engineer. Clarkson University - Mechanical & Civil Engineering BS, Matthew KaneCOOOperations Guru. Leader in quality systems, operations, & FDA regulatory strategy. Clarkson University - Aeronautical & Mechanical Engineering BS. University of Notre Dame - Aerospace Engineering MSc, Surbhi SarnaInvestor & AdvisorHealthcare partner at Y-Combinator. Medical device & pharmaceutical industry experience. Founder of nVision, acquired by Boston Scientific for $270M. Board Director at Penumbra Medical, Biora, Omniscient Neurotechnology, YourChoice Therapeutic, & AOA, Parinaz MotemedyInvestor, Board MemberPartner at Safar Partners ($800M AUM). Previously led investments for AccorHotels, Europe’s #1 largest hospitality company. Former Blackstone ($1T AUM). Harvard University - Philosophy BA
Amount Raised : $5,856,175
Reveal the Score by Voting
_
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.
Valuation

Security Description

A CAFES (Contract and Future Equity Stake) can convert into different types of equity upon a Triggering Event, such as: common or preferred stock for a corporation, limited partnership interest for a limited partnership and membership interest for a limited liability company. At the time of the Triggering Event, the specific rights and limitations associated with the equity stake being issued to the investors will be determined and disclosed by the Entrepreneur.

Research Reports

No reports have been submitted

Become a Reporter

0 Comments